Anticancer drug market: Enjoy the "golden decade" of pharmaceutical growth

The anti-cancer drug market is benefiting from the high growth of the pharmaceutical industry in China. At present, China's pharmaceutical industry is in a period of rapid growth. Although China's total health expenditure as a percentage of GDP is still at a low level (less than 5%), compared with developed countries such as the United States (17%), there is still a considerable gap, but in recent years, But it is constantly climbing. The pharmaceutical industry, which is in an overall rising position, will inevitably drive the booming market of anticancer drugs. At the same time, as the scale of sales increases year by year, anti-cancer drugs are increasingly becoming an indispensable force for the rapid growth of the pharmaceutical industry.

Aging and urbanization drive demand for anticancer drugs. In the past 30 years, the death rate of cancer in China has increased by 80%. The annual incidence of cancer is about 2.6 million and the death toll is about 1.8 million. The main causes of the rising incidence of cancer are various objective factors such as changes in the living environment, methods, and pressures for survival. Among them, aging and urbanization are the two most important factors.

Anti-cancer drug patent expiration, generic drugs import alternative usher in opportunities. The development of global new drugs is difficult, pharmaceutical companies have turned to generic drugs, and the corresponding generic drug market will expand rapidly. In the face of a huge domestic market, the replacement of generic drugs will welcome new opportunities.

The market for chemotherapeutic drugs has matured and the targeted drug market has grown rapidly. The entire chemotherapy market has matured and steadily increased. Among them, paclitaxel and docetaxel are commonly used drugs for the clinical treatment of cancer. In 2009, both accounted for 21% of the market share of anticancer drug products in China. Targeted therapeutic drugs are the new force for the rapid rise of anti-cancer drugs in recent years. By 2015, the global market for targeted therapeutic drugs is expected to exceed 50 billion U.S. dollars, with a compound annual growth rate of 11%, and there will be more than 8 new drugs in this area becoming market-leading products.

The strong R&D strength and rich new drug reserves are the core advantages of the industry leader. The global giants of anti-cancer drug production have strong drug research and development teams, and R&D investment accounts for 15% to 20% of total revenue each year. The investment in research and development of China's leading manufacturers of anti-cancer drugs is about 8%. There is still a certain gap with the world's giants, but it is far higher than the average level of China's pharmaceutical and biological industries, which fully demonstrates the anti-cancer drug sub-sector. It is a relatively high-end pharmaceutical field and a concrete embodiment of the industry's high barriers. Due to the long cycle and high risk of drug development, the continuity of new drugs in R&D, production, and storage has become a business strategy that manufacturers cannot ignore.